JP2017515849A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515849A5
JP2017515849A5 JP2016567529A JP2016567529A JP2017515849A5 JP 2017515849 A5 JP2017515849 A5 JP 2017515849A5 JP 2016567529 A JP2016567529 A JP 2016567529A JP 2016567529 A JP2016567529 A JP 2016567529A JP 2017515849 A5 JP2017515849 A5 JP 2017515849A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oral dosage
dasotorarin
dosage form
adhd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016567529A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515849A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/030357 external-priority patent/WO2015175523A1/en
Publication of JP2017515849A publication Critical patent/JP2017515849A/ja
Publication of JP2017515849A5 publication Critical patent/JP2017515849A5/ja
Pending legal-status Critical Current

Links

JP2016567529A 2014-05-13 2015-05-12 Adhdを治療するためのダソトラリン用量および治療方法 Pending JP2017515849A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992619P 2014-05-13 2014-05-13
US61/992,619 2014-05-13
PCT/US2015/030357 WO2015175523A1 (en) 2014-05-13 2015-05-12 Dosage of dasotraline and method for treatment of adhd

Publications (2)

Publication Number Publication Date
JP2017515849A JP2017515849A (ja) 2017-06-15
JP2017515849A5 true JP2017515849A5 (cg-RX-API-DMAC7.html) 2018-06-21

Family

ID=54480549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567529A Pending JP2017515849A (ja) 2014-05-13 2015-05-12 Adhdを治療するためのダソトラリン用量および治療方法

Country Status (10)

Country Link
US (1) US10076503B2 (cg-RX-API-DMAC7.html)
EP (1) EP3143000A4 (cg-RX-API-DMAC7.html)
JP (1) JP2017515849A (cg-RX-API-DMAC7.html)
KR (1) KR20170005088A (cg-RX-API-DMAC7.html)
CN (1) CN106660937A (cg-RX-API-DMAC7.html)
AU (1) AU2015259346A1 (cg-RX-API-DMAC7.html)
CA (1) CA2948839A1 (cg-RX-API-DMAC7.html)
IL (1) IL248847A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016014768A (cg-RX-API-DMAC7.html)
WO (1) WO2015175523A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092496A1 (en) * 2018-10-31 2020-05-07 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
ES2431519T3 (es) * 2002-09-16 2013-11-26 Sepracor, Inc. trans-4-(3,4-Diclorofenil)-1,2,3,4-tetrahidro-1-naftalenamina para su uso en el tratamiento de trastornos del SNC
AU2010325894B2 (en) * 2009-12-04 2015-07-30 Sunovion Pharmaceuticals Inc. Formulations, salts and polymorphs of transnorsertraline and uses thereof

Similar Documents

Publication Publication Date Title
JP2012193216A5 (cg-RX-API-DMAC7.html)
MX2024010140A (es) Nuevos metodos.
MX2018008021A (es) Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
JP2013155188A5 (cg-RX-API-DMAC7.html)
JP2016163571A5 (cg-RX-API-DMAC7.html)
JP2015057451A5 (cg-RX-API-DMAC7.html)
JP2015083580A5 (cg-RX-API-DMAC7.html)
JP2017506624A5 (cg-RX-API-DMAC7.html)
JP2016106150A5 (cg-RX-API-DMAC7.html)
JP2016147915A5 (cg-RX-API-DMAC7.html)
JP2015038135A5 (cg-RX-API-DMAC7.html)
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
JP2015537009A5 (cg-RX-API-DMAC7.html)
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
JP2013166781A5 (cg-RX-API-DMAC7.html)
JP2016527312A5 (ja) ヒスタミンh4受容体を介してもたらされた掻痒状態を治療するための医薬組成物
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
JP2020529995A5 (cg-RX-API-DMAC7.html)
FI2683245T4 (fi) Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä
JP2015507020A5 (cg-RX-API-DMAC7.html)
JP2017061488A5 (cg-RX-API-DMAC7.html)
JP2017516842A5 (cg-RX-API-DMAC7.html)
JP2017515849A5 (cg-RX-API-DMAC7.html)
JP2015512948A5 (cg-RX-API-DMAC7.html)